Administration Defines Benefits That Must Be Offered Under the Health Law

Published Online: November 21, 2012
WASHINGTON — The Obama administration took a big step on Tuesday to carry out the new health care law by defining “essential health benefits” that must be offered to most Americans and by allowing employers to offer much bigger financial rewards to employees who quit smoking or adopt other healthy behaviors.

The proposed rules, issued more than two and a half years after President Obama signed the Affordable Care Act, had been delayed as the administration tried to avoid stirring criticism from lobbyists and interest groups in the final weeks of the presidential campaign.

Read the full story: http://nyti.ms/108TpTY

Source: The New York Times

Feature
Recommended Articles
The deal combines Humana's 3.2 million Medicare enrollees with Aetna's 1.26 million Medicare enrollees, giving the new combined company a strong position as the baby boomer population ages.
New delivery models related to the recent healthcare reform legislation may help drive up utilization, as discussed by Francois de Brantes, MS, MBA; Ateev Mehrotra, MD, MPH; and Arthur Vercillo, MD, FACS, in this seventh segment of the Healthcare Reform Stakeholders Summit, Spring 2015 series. They theorize that healthcare convenience and availability may actually lead to a loss in coordination of care.
The fact that a small percentage of the population accounts for roughly half of healthcare spending in the United States is not new information. Now a new white paper from the Health Care Transformation Task Force has taken a look at what healthcare systems can do to identify these individuals in order to better manage their care and lower spending.
When The American Journal of Managed Care’s ACO and Emerging Healthcare Delivery Coalition met for the most recent Web-based session, the speakers discussed the importance of accountable care organizations as CMS moves forward with new reimbursement schemes and managing high-risk patients through coordinated care.
Heterogeneity in Medicaid coverage of the anti-viral agent sofosbuvir is rampant across the United States, with varying reimbursement criteria and lack of conformation to recommendations by professional infectious disease organizations.